查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年个人化医疗市场预测：按产品、应用、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383451

到 2030 年个人化医疗市场预测：按产品、应用、最终用户和地区进行的全球分析

Personalized Medicine Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球个人化医疗市场规模为 3,390 亿美元，预计在预测期内将以 13.0% 的年复合成长率成长，到 2030 年达到 7,970 亿美元。

个人化医疗在很大程度上依赖药物基因组学测试。透过确定患者的基因组成如何影响治疗反应，医疗专业人员可以为每位患者选择最安全、最有效的药物和剂量。透过发现特定的基因突变并开发针对这些问题根源的药物，个人化医疗正在彻底改变罕见疾病的诊断和治疗。

据世界卫生组织 (WHO) 称，癌症是世界上第一大死亡原因，2018 年估计有 960 万人死亡。这意味着全世界大约六分之一的人将死于癌症。

标靶治疗的兴起

个人化医疗领域极大地受益于标靶治疗的出现。个人化医疗的一个基本要素是标靶治疗，它是专门针对患者疾病的遗传或分子方面而创建的。将标靶治疗治疗与标准治疗进行比较时，优点之一是减少副作用。此外，与传统的一刀切治疗方法相比，根据患者的遗传和分子特征量身定制治疗可降低副作用的可能性，并且通常会产生更好的治疗结果。透过识别最有可能从此类药物中受益的患者，个人化医疗增加了成功的可能性。

高成本

高昂的费用可能会成为进入的障碍，而个体化的治疗可能会保留给有能力获得的人。这可能会导致医疗保健方面的不平等，有些人可以获得个体化的、最最先进治疗，而有些人则无法获得。个体化药物治疗的高昂成本可能会对医疗保健预算造成压力，并使保险公司和卫生系统难以承保。这可能会限制国家和地方医疗保健系统可以提供的最先进治疗的数量。由于个人化医疗价格昂贵，有些患者可能不愿意接受个人化医疗，错过了接受更安全、更成功的个人化医疗，这种情况也有可能发生。

提高药物开发效率

在高效药物开发系统的支持下，科学发现和研究成果可以更快转化为实际治疗方法。因此，患者将受益于遗传学和分子生物学的最新进展，更快更快地接受客製化治疗方法。此外，透过更有效的药物开发有望降低成本。因此，更广泛的患者可能会受益并获得个人化药物，这些药物变得更加便宜和可用，从而推动市场成长。

可及性有限

如果个人化药物不能广泛使用，医疗保健差距可能会加剧。如果个体化治疗的患者接受较差或无效的治疗，而无法负担这些服务的患者接受较差或无效的治疗，则可能会出现不同的健康结果。成本考量可能会限制患者选择个体化治疗的能力，并减少他们对医疗保健的自主权。获得个人化医疗的人数减少可能意味着缺乏对该领域的研究和治疗结果至关重要的多样化患者资料。资料不足可能会阻碍新治疗方法和诊断的进展。

COVID-19 的影响

医疗保健系统和资源对 COVID-19 大流行的最初反应是为了控制和遏制病毒。非紧急医疗活动的大量资金被挪用，其中包括一些有针对性的医疗计划。个人化医疗计划可以受益于大流行期间远端医疗和远端监控的显着增加。远距医疗使得收集患者资料并将其纳入个体化治疗方法成为可能，特别是慢性病和心理健康问题的管理，对市场成长有正面影响。

个人化医疗治疗领域预计在预测期内规模最大

由于基因组序列测定技术的进步以及遗传和分子资料获取的增加，个人化个人化医疗市场正在稳步扩大，因此个人化医疗领域预计将出现良好的成长。随着分子生物学和遗传学知识的扩展，这种增长预计将持续下去。遗传咨询师越来越积极教育病人遗传资讯对健康的影响。这是个人化治疗的重要组成部分，因为患者做出明智的决定非常重要。

预计医学领域在预测期内的年复合成长率最高。

预计精神病学领域在预测期内将出现最高的年复合成长率年增长率，因为它对于确定哪些精神药物最有效以及哪些可能引起副作用非常有用。基因检测和生物标记研究可以帮助预测患者对某些精神药物的反应。这使医疗保健专业人员摆脱了确定治疗精神疾病典型的适当处方和剂量的试验（有时是漫长的过程）。糖尿病和心血管疾病等合併症在精神疾病患者中很常见。

比最大的地区

由于雅培、Qiagen、GE Healthcare 和BASF SE 等许多重要公司的存在，预计北美在预测期内将占据最大的市场占有率。此外，北美地区糖尿病、心臟病和癌症等慢性病的盛行率不断增加，推动了对客製化医疗解决方案的需求，以提供更有针对性和更有效的治疗。此外，北美拥有高度复杂的医疗保健系统，高度重视创新和最尖端科技的实施。因此，客製化医疗技术正在兴起并在该地区广泛应用。

复合年复合成长率最高的地区：

预计亚太地区在预测期内的年复合成长率最高。这是由于该地区製药公司的存在以及中国和印度等人口大国购买力的不断上升推动了市场扩张。此外，由于个体化药物成本不断上升，以及使用高科技处理来增强客製化解决方案的创建，预计该市场将会发展。此外，亚太地区人口正在显着增长，这增加了对更个体化医疗保健（包括个体化药物）的需求。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球个人化医疗市场：依产品

  • 个人化医疗
    • 药品
    • 医疗设备
    • 基因组医学
  • 个人化医疗诊断
    • 深奥实验室服务
    • 直接面向消费者 (DTC) 诊断
    • 基因检测
    • 困难的实验室测试
  • 个体化医疗
    • 健康资讯技术
    • 远端医疗
  • 个人化营养与健康
    • 补充和替代医学
    • 零售营养品
  • 其他产品

第6章全球个人化医疗市场：依应用分类

  • 心臟病学
  • 肿瘤学
  • 抗病毒药
  • 精神病学
  • 神经病学
  • 免疫学
  • 其他用途

第7章全球个人化医疗市场：依最终用户分类

  • 医院
  • 研究/学术机构
  • 诊断中心
  • 其他最终用户

第8章全球个人化医疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Decode Genetics
  • QIAGEN
  • Precision Biologics
  • Biogen
  • Genelex
  • IBM
  • Genentech, Inc.
  • 23andMe, Inc
  • GE Healthcare
  • Illumina, Inc
  • ASURAGEN
  • Aadi Bioscience, Inc.
  • Takeda Pharmaceutical Company Ltd
  • ARIEL Precision Medicine, Inc.
  • Hoffmann-La Roche Ltd.
  • Abbvie Inc
  • Eli Lilly and Company
Product Code: SMRC24299

According to Stratistics MRC, the Global Personalized Medicine Market is accounted for $339 billion in 2023 and is expected to reach $797 billion by 2030 growing at a CAGR of 13.0% during the forecast period. Personalized medicine heavily relies on pharmacogenomic testing. It makes it possible for medical professionals to select the safest and most effective medications and doses for each patient by identifying how a person's genetic composition influences how they respond to treatment. By discovering certain genetic variants and creating medicines that target the underlying causes of these problems, personalized medicine is revolutionizing the diagnosis and treatment of uncommon diseases.

Cancer is the biggest cause of mortality worldwide, according to the World Health Organization (WHO), with an estimated 9.6 million deaths in 2018. This means that cancer is responsible for around 1 in every 6 deaths worldwide.

Market Dynamics:

Driver:

Rise in targeted therapies

The discipline of customized medicine has greatly benefited by the advent of targeted medicines. One essential element of personalized medicine is targeted medicines, which are created to explicitly target the genetic or molecular aspects of a patient's illness. Comparing targeted therapies to standard treatments, one benefit is the decrease in adverse effects. Moreover, the probability of side effects is reduced by customizing therapies based on a patient's genetic or molecular profile, comparing targeted therapy to conventional, one-size-fits-all methods; greater treatment outcomes are frequently achieved. By identifying patients who are most likely to benefit from these medicines, personalized medicine increases the likelihood of success.

Restraint:

High cost

Exorbitant expenses may erect obstacles to entry, reserving tailored treatment for those with the means to obtain it. Healthcare inequalities may arise from this, with certain individuals receiving individualized, cutting-edge therapies while others lack access to them. Budgets for healthcare may be strained by the high expenses of individualized medication, which insurers and healthcare systems may find difficult to cover. This may restrict the number of these cutting-edge therapies that are offered by national or local healthcare systems. Because personalized medicine can be expensive, some patients may decide not to seek it and this could lead to missed chances for individualized therapies that might be safer and more successful.

Opportunity:

Drug development efficiency

Scientific discoveries and research findings may be translated into practical therapies more swiftly with the aid of efficient drug development systems. As a result, patients will benefit from customized therapy sooner and more quickly from the most recent advances in genetics and molecular biology. Additionally, the cost reductions may result from more effective medication development. Thus, a wider range of patients may benefit from and be able to acquire customized medications due to their increased affordability and accessibility thereby enhancing the growth of the market.

Threat:

Limited accessibility

Healthcare disparities may worsen if tailored medication is not widely available. There may be differences in health outcomes if patients who can afford individualized therapies receive subpar or ineffective care, while those who cannot afford these services may receive subpar or ineffective care. Cost considerations may prevent patients from selecting individualized therapy, which would reduce their autonomy over their medical care, less people having access to customized medicine might mean a lack of diverse patient data, which is essential for the field's achievements in research and treatment, insufficient data can impede the advancement of novel treatments and diagnostics.

COVID-19 Impact

Healthcare systems' and resources' first response to the COVID-19 pandemic has redirected them toward controlling and containing the virus. Numerous funds, including some targeted medicine projects, were taken away from non-urgent medical operations. Personalized medicine projects can benefit from the huge increase in telemedicine and remote monitoring that occurred during the epidemic. Remote consultations have made it possible to gather patient data and incorporate it into individualized treatment regimens, particularly for the management of chronic illnesses and mental health issues which has positively impacted the market growth.

The personalized medicine therapeutics segment is expected to be the largest during the forecast period

The personalized medicine therapeutics segment is estimated to have a lucrative growth, as this market for customized medicine has been steadily expanding due to developments in genomic sequencing technology and the growing accessibility of genetic and molecular data. It is anticipated that this rise will continue in the upcoming years as our knowledge of molecular biology and genetics expands. Genetic counselors are becoming more and more active in educating patients about the effects of their genetic information on their health. This is a vital part of customized treatment since it is important for patients to make educated decisions.

The psychiatry segment is expected to have the highest CAGR during the forecast period

The psychiatry segment is anticipated to witness the highest CAGR growth during the forecast period, as this can be very helpful in psychiatry when figuring out which psychotropic drugs are most likely to work and which can have negative side effects. Predicting a patient's reaction to particular psychiatric drugs can be aided by genetic testing and biomarker research. This spares medical professionals from the sometimes drawn-out process of trial and error involved in determining the appropriate prescription and dose, which is typical in the treatment of mental illness. Comorbid diseases like diabetes or cardiovascular problems are common in people with mental illnesses.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the existence of many significant companies, including Abbott, Qiagen, GE Healthcare, and BASF SE. Furthermore, the rising rate of chronic illnesses in North America, including diabetes, heart disease, and cancer, is driving up demand for customized medical solutions that offer more focused and efficient therapies. Additionally, North America boasts a very sophisticated healthcare system that places a high value on innovation and the uptake of cutting-edge technologies. This has made it possible for customized medical technologies to emerge and become widely used in the area.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing the presence of pharmaceutical businesses in the area and the rise in the purchasing power of populous nations like China and India are responsible for the market's expansion. Additionally, it is projected that the market will develop due to an increase in the cost of personalized medication and the use of high-tech processing to enhance the creation of tailored solutions. Moreover, the Asia-Pacific area has a sizable and expanding population, which is increasing the need for more individualized medical treatments, including individualized medications.

Key players in the market

Some of the key players profiled in the Personalized Medicine Market include: Abbott, Dako A/S, Exact Sciences Corporation, Decode Genetics, QIAGEN, Precision Biologics, Biogen, Genelex, IBM, Genentech, Inc., 23andMe, Inc, GE Healthcare, Illumina, Inc, ASURAGEN, Aadi Bioscience, Inc., Takeda Pharmaceutical Company Ltd, ARIEL Precision Medicine, Inc., Hoffmann-La Roche Ltd., Abbvie Inc and Eli Lilly and Company

Key Developments:

In November 2023, Abbott has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays.

In October 2023, Exact Sciences Corp. announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or recurrent cancer.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Products Covered:

  • Personalized Medicine Therapeutics
  • Personalized Medicine Diagnostics
  • Personalized Medical Care
  • Personalized Nutrition & Wellness
  • Other Products

Applications Covered:

  • Cardiology
  • Oncology
  • Antiviral
  • Psychiatry
  • Neurology
  • Immunology
  • Other Applications

End Users Covered:

  • Hospitals
  • Research & Academic Institutes
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Medicine Market, By Product

  • 5.1 Introduction
  • 5.2 Personalized Medicine Therapeutics
    • 5.2.1 Pharmaceutical
    • 5.2.2 Medical Devices
    • 5.2.3 Genomic Medicine
  • 5.3 Personalized Medicine Diagnostics
    • 5.3.1 Esoteric Lab Services
    • 5.3.2 Direct-To-Consumer (DTC) Diagnostics
    • 5.3.3 Genetic Testing
    • 5.3.4 Esoteric Lab Tests
  • 5.4 Personalized Medical Care
    • 5.4.1 Health Information Technology
    • 5.4.2 Telemedicine
  • 5.5 Personalized Nutrition & Wellness
    • 5.5.1 Complementary & Alternative Medicine
    • 5.5.2 Retail Nutrition
  • 5.6 Other Products

6 Global Personalized Medicine Market, By Application

  • 6.1 Introduction
  • 6.2 Cardiology
  • 6.3 Oncology
  • 6.4 Antiviral
  • 6.5 Psychiatry
  • 6.6 Neurology
  • 6.7 Immunology
  • 6.8 Other Applications

7 Global Personalized Medicine Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Research & Academic Institutes
  • 7.4 Diagnostic Centers
  • 7.5 Other End Users

8 Global Personalized Medicine Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott
  • 10.2 Dako A/S
  • 10.3 Exact Sciences Corporation
  • 10.4 Decode Genetics
  • 10.5 QIAGEN
  • 10.6 Precision Biologics
  • 10.7 Biogen
  • 10.8 Genelex
  • 10.9 IBM
  • 10.10 Genentech, Inc.
  • 10.11 23andMe, Inc
  • 10.12 GE Healthcare
  • 10.13 Illumina, Inc
  • 10.14 ASURAGEN
  • 10.15 Aadi Bioscience, Inc.
  • 10.16 Takeda Pharmaceutical Company Ltd
  • 10.17 ARIEL Precision Medicine, Inc.
  • 10.18 Hoffmann-La Roche Ltd.
  • 10.19 Abbvie Inc
  • 10.20 Eli Lilly and Company

List of Tables

  • Table 1 Global Personalized Medicine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Personalized Medicine Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Personalized Medicine Market Outlook, By Personalized Medicine Therapeutics (2021-2030) ($MN)
  • Table 4 Global Personalized Medicine Market Outlook, By Pharmaceutical (2021-2030) ($MN)
  • Table 5 Global Personalized Medicine Market Outlook, By Medical Devices (2021-2030) ($MN)
  • Table 6 Global Personalized Medicine Market Outlook, By Genomic Medicine (2021-2030) ($MN)
  • Table 7 Global Personalized Medicine Market Outlook, By Personalized Medicine Diagnostics (2021-2030) ($MN)
  • Table 8 Global Personalized Medicine Market Outlook, By Esoteric Lab Services (2021-2030) ($MN)
  • Table 9 Global Personalized Medicine Market Outlook, By Direct-To-Consumer (DTC) Diagnostics (2021-2030) ($MN)
  • Table 10 Global Personalized Medicine Market Outlook, By Genetic Testing (2021-2030) ($MN)
  • Table 11 Global Personalized Medicine Market Outlook, By Esoteric Lab Tests (2021-2030) ($MN)
  • Table 12 Global Personalized Medicine Market Outlook, By Personalized Medical Care (2021-2030) ($MN)
  • Table 13 Global Personalized Medicine Market Outlook, By Health Information Technology (2021-2030) ($MN)
  • Table 14 Global Personalized Medicine Market Outlook, By Telemedicine (2021-2030) ($MN)
  • Table 15 Global Personalized Medicine Market Outlook, By Personalized Nutrition & Wellness (2021-2030) ($MN)
  • Table 16 Global Personalized Medicine Market Outlook, By Complementary & Alternative Medicine (2021-2030) ($MN)
  • Table 17 Global Personalized Medicine Market Outlook, By Retail Nutrition (2021-2030) ($MN)
  • Table 18 Global Personalized Medicine Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 19 Global Personalized Medicine Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Personalized Medicine Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 21 Global Personalized Medicine Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 22 Global Personalized Medicine Market Outlook, By Antiviral (2021-2030) ($MN)
  • Table 23 Global Personalized Medicine Market Outlook, By Psychiatry (2021-2030) ($MN)
  • Table 24 Global Personalized Medicine Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 25 Global Personalized Medicine Market Outlook, By Immunology (2021-2030) ($MN)
  • Table 26 Global Personalized Medicine Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 27 Global Personalized Medicine Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 Global Personalized Medicine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Personalized Medicine Market Outlook, By Research & Academic Institutes (2021-2030) ($MN)
  • Table 30 Global Personalized Medicine Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 31 Global Personalized Medicine Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.